Literature DB >> 12805341

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.

Andrés J M Ferreri1, Lauren E Abrey, Jean-Yves Blay, Bettina Borisch, Jacob Hochman, Edward A Neuwelt, Joachim Yahalom, Emanuele Zucca, Franco Cavalli, James Armitage, Tracy Batchelor.   

Abstract

Under the sponsorship of the International Extranodal Lymphoma Study Group, a Multidisciplinary Workshop on primary CNS lymphoma (PCNSL) with over 50 participants from Europe, North America, Israel, and Australia was held as part of the Eighth International Conference on Malignant Lymphoma in Lugano, Switzerland (June 12 to 15, 2002). The main purposes of the Workshop were to exchange the latest scientific information, to analyze methodologic issues in the design of clinical trials, to reach a consensus on treatment recommendations and prognostic factors, to discuss clinical and molecular targets for future studies, and to establish an international collaborative group to conduct laboratory and clinical investigations in PCNSL. This article summarizes the contents of the Workshop, analyzes the current knowledge on the most relevant biologic and clinical issues in PCNSL, and focuses on fundamental challenges to be addressed in future studies.

Entities:  

Mesh:

Year:  2003        PMID: 12805341     DOI: 10.1200/JCO.2003.01.135

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  [Diagnosis of an initial infratentorial central nervous system B-cell lymphoma during prolonged cortisone medication].

Authors:  A Buss; A Assmus; J Weidemann; B Sellhaus; J Lorenzen; F Block
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

Review 2.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

3.  Clinical reasoning: a 51-year-old man with cervical pain and progressively deteriorating gait.

Authors:  Dimitrios Rallis; Panagiotis Tsirigotis; Chryssa Arvaniti; Spiros Sgouros; Periclis G Foukas; Nikolaos Oikonomopoulos; Nikolaos Andronas; Ioannis G Panayiotides; Vasilios Kouloulias; Sotirios Papageorgiou; Konstantinos Voumvourakis; Eleftherios Stamboulis
Journal:  Neurology       Date:  2013-05-28       Impact factor: 9.910

4.  Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.

Authors:  Michael Linnebank; Susanna Moskau; Annika Jürgens; Matthias Simon; Alexander Semmler; Katjana Orlopp; Axel Glasmacher; Christopher Bangard; Marlies Vogt-Schaden; Horst Urbach; Ingo G H Schmidt-Wolf; Hendrik Pels; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2008-09-19       Impact factor: 12.300

5.  Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Authors:  Keishi Makino; Hideo Nakamura; Taku-Ichiro Hide; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

6.  Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.

Authors:  Jong Hyung Yoon; Hyoung Jin Kang; Hyery Kim; Ji Won Lee; June Dong Park; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

7.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

Review 8.  Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.

Authors:  James Rubenstein; Andrés J M Ferreri; Stefania Pittaluga
Journal:  Leuk Lymphoma       Date:  2008

9.  Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Authors:  M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

10.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.